Characterization of two common 5' polymorphisms in  and correlation to survival in PEX1 peroxisome biogenesis disorder patients by unknown
RESEARCH ARTICLE Open Access
Characterization of two common 5’ polymorphisms
in PEX1 and correlation to survival in PEX1
peroxisome biogenesis disorder patients
Sven Thoms*†, Sabine Grønborg†, Jana Rabenau, Andreas Ohlenbusch, Hendrik Rosewich and Jutta Gärtner
Abstract
Background: Mutations in PEX1 are the most common primary cause of Zellweger syndrome. In addition to
exonic mutations, deletions and splice site mutations two 5’ polymorphisms at c.-137 and c.-53 with a potential
influence on PEX1 protein levels have been described in the 5’ untranslated region (UTR) of the PEX1 gene.
Methods: We used RACE and in silico promoter prediction analysis to study the 5’ UTR of PEX1. We determined
the distribution of PEX1 5’ polymorphisms in a cohort of 30 Zellweger syndrome patients by standard DNA
sequencing. 5’ polymorphisms were analysed in relation to the two most common mutations in PEX1 and were
incorporated into a novel genotype-phenotype analysis by correlation of three classes of PEX1 mutations with
patient survival.
Results: We provide evidence that the polymorphism 137 bp upstream of the ATG codon is not part of the UTR,
rendering it a promoter polymorphism. We show that the first, but not the second most common PEX1 mutation
arose independently of a specific upstream polymorphic constellation. By genotype-phenotype analysis we
identified patients with identical exonic mutation and identical 5’ polymorphisms, but strongly differing survival.
Conclusions: Our study suggests that two different types of PEX1 5’ polymorphisms have to be distinguished: a 5’
UTR polymorphism at position c.-53 and a promoter polymorphism 137 bp upstream of the PEX1 start codon. Our
results indicate that the exonic PEX1 mutation correlates with patient survival, but the two 5’ polymorphisms
analysed in this study do not have to be considered for diagnostic and/or prognostic purposes.
Background
Peroxisome biogenesis disorders (PBD, MIM #601539)
are a group of autosomal recessive diseases characterized
by a severe developmental and metabolic phenotype [1].
PBD comprise the Zellweger syndrome (ZS) spectrum
and rhizomelic chondrodysplasia punctata. The ZS spec-
trum consists of three overlapping clinical phenotypes
representing a continuum of disorders, ranging form
infantile Refsum disease (IRD, MIM #266510) as the
mildest variant, to neonatal adrenoleukodystrophy
(NALD, #MIM 202370) and to ZS (MIM #214100) as the
prototype and most severe form with a life expectancy of
less than one year. ZS patients often show characteristic
dysmorphic features and severe neurodevelopmental
brain abnormalities like polymicrogyria and pachygyria.
Clinically patients present with muscular hypotonia and
poor feeding, seizures, eye abnormalities, liver dysfunc-
tion and skeletal defects.
ZS is caused by mutations in PEX genes, encoding pro-
teins (peroxins) required for the biogenesis of peroxi-
somes [1,2]. Peroxisomes are ubiquitous cellular
organelles with functions in ether lipid biosynthesis, a-
oxidation of phytanic acid, b-oxidation of very long chain
fatty acids (VLCFAs) and of bile acid precursors and doc-
osahexaenoic acid (DHA) precursors, and in hydrogen
peroxide metabolism [3]. Peroxisomes are versatile orga-
nelles which can be induced and regulated according to
metabolic needs [4]. In humans, 16 evolutionarily con-
served peroxins are known, mutations in 13 of which are
associated with disease. The peroxins PEX5 and PEX7
are cytosol-based import receptors for peroxisomal
matrix proteins. The import receptor PEX5 loaded with
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matrix proteins can associate with most peroxisomal pro-
teins in the cytosol and is involved in the translocation of
these proteins into the peroxisome. According to one
model, a downstream complex of two ATPases, PEX1
and PEX6, and the peroxisomal membrane protein
PEX26 are thought to mediate recycling of PEX5 into the
cytosol [5,6]. This process depends on ubiquitination of
PEX5 during the translocation process at the peroxisomal
membrane. Models of peroxisome protein import have
been reviewed recently [7,8].
PEX1 and the paralogous PEX6 gene encode members of
the AAA (ATPases associated with diverse cellular activ-
ities) family of proteins. PEX1 and PEX6 comprise two
AAA domains. The PEX1 gene spans about 41.5 Mbp and
is composed of 24 exons, encoding an mRNA of 4.4 kbp.
Mutations in PEX1 are the most common primary cause of
Zellweger syndrome and account for roughly two thirds of
all PBD patients [9-14]. The most commonly found muta-
tion in PEX1 is c.2528G > A leading to an exchange of Gly
to Asp in the PEX1 protein [15-17]. The second most fre-
quent mutation is the insertion 2097_2098insT leading to a
frameshift and nonsense mutation after I700 [9,18]. These
common PEX1 mutations have been included in genotype
phenotype analyses showing that the missense mutation is
associated with the mild end of the clinical spectrum and
the insertion with more severly affected patients [1]. This
correlation proves true in the majority of cases, but excep-
tions can be observed in which same genetic constellation
leads to largely divergent phenotypes. Such cases make it
necessary to look for potential effects that modulate patient
outcome on the basis of a given primary defect. More
recently, two polymorphisms have been described
upstream the PEX1 coding region. One is a C-to-G trans-
version located 53 nucleotides upstream the PEX1 ATG
(c.-53C > G). The other is a T-to-C transition, c.-137T > C.
The c.-137 T > C polymorphism resides in a potential in-
frame ATG codon that could expand the PEX1 ORF by
138 bp. This ATG, however, could be shown not to repre-
sent a translational start codon [19]. Reporter studies by
Maxwell et al. suggest that the -137C polymorphism results
in reduced expression of PEX1 whereas the -53G poly-
morphism increases expression of PEX1 [19]. A combina-
tion of both polymorphisms results in near-normal
expression of PEX1 in a reporter experiment [19]. Poly-
morphisms modulating the PEX1 protein level could possi-
bly modulate the disease phenotype of PEX1 patients. An
analysis of polymorphisms and PEX1 mutations in 25
PEX1-deficient patients suggested that the c.-137T > C
transition cosegregates with the c.-53C > G transversion.
In addition, both polymorphisms were found to cosegre-
gate with the 2097_2098insT mutation [19].
To evaluate the potential influence of known 5’ poly-
morphisms in PEX1 on the disease phenotype we analysed
the 5’ UTR in more detail. We provide evidence that the
-137C polymorphism is not a 5’ UTR but rather a promo-
ter polymorphism. We included both polymorphisms in a
genotype-phenotype analysis of 30 PBD patients with




5’UTR polymorphisms of 30 patients with mutations in
the PEX1 gene were analyzed. The patients had been
referred to the Department of Pediatrics and Pediatric
Neurology at the University of Göttingen for diagnostic
evaluation of peroxisome biogenesis disorder and through
the German LEUKONET. Informed consent has been
obtained from guardians of all patients. The work pre-
sented in this study was conducted under the approval of
the local ethics committee. The clinical phenotype and
plasma biochemical abnormalities pointed towards a per-
oxisome biogenesis disorder and PEX1 gene mutations
were identified by direct sequencing. PEX1 mutations of
this patient cohort are previously published in part [12]. In
some instances PEX1 deficiency was further confirmed by
complementation analysis [14].
Extraction of genomic DNA from fibroblasts and blood
Genomic DNA was extracted from 107 cells. After trypsi-
nization, cells were washed in PBS, resuspended in 800 μl
lysis buffer (50 mM Tris-HCl, pH 8.0, 100 mM EDTA,
0.5% SDS) and treated with 50 μg proteinase K for 16 hrs
at 55°C. DNA was extracted by a standard protocol using
phenol-chloroform. Genomic DNA from blood was
extracted using the DNeasy Blood&Tissue Kit (Qiagen,
Hilden, Germany) following the instructions of the
manufacturer.
RNA extraction and cDNA-Synthesis (Reverse
Transcription)
RNA was extracted from fibroblasts using peqGOLD
TriFast (Peqlab, Erlangen, Germany). For first strand
synthesis we used the SuperScriptIII First-Strand Synth-
esis System (Invitrogen, Darmstadt, Germany) with 1 μg
total RNA together with Oligo(dT20) primers according
to the specification of the manufacturer.
Determination of polymorphisms and haplotype analysis
Single nucleotide polymorphisms at c.-53 C > G und c.-
137 T > C in the PEX1 gene, and exonic mutations were
analysed by sequencing after PCR amplification using the
primers listed in the table in additional file 1. PCR reac-
tions were performed in a Thermocycler T3000 (Biometra,
Göttingen, Germany) and analysed on 1% agarose gels. All
PCR products were purified using the High Pure PCR Pur-
ification Kit (Roche, Grenzach-Wyhlen, Germany) follow-
ing the instructions of the manufacturer. For DNA
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sequencing the BigDyeTerminator v3.1 Cycle Sequencing
kit (Applied Biosystems, Darmstadt, Germany) was used.
Sequencing reactions were purified by DNA precipitation,
dissolved in 10 μl Hi-Di formamid (Applied Biosystems)
and analysed on a 3100-Avant Genetic Analyzer (Applied
Biosystems). Abi Prism 3100 Genetic Analyzer Data Col-
lection Software 2.0 (Applied Biosystems) and Laser Gene
Sequencing Analysis Software 5.1. (Dnastar, Madison, WI,
USA) were used for sequence analysis.
Rapid amplification of cDNA ends (RACE)
The 5’/3’ RACE Kit (Roche) was used to characterize the
transcriptional start of the PEX1 mRNA following the
manufacturer’s protocol. Briefly, PEX1 specific reverse pri-
mers (SP1, SP2, SP3, respectively) and Reverse Transcrip-
tase were used to synthesize cDNA extending to the 5’
end of the PEX1 mRNA. The 3’ end of the resulting
cDNA was polyadenylated using Terminal Transferase.
The resulting cDNA was PCR amplified using internal
PEX1 specific primers (SP2, Pex1ex2, SP1, respectively),
and an oligo-dT anchor primer. This step was followed by
a nested PCR (primers Pec10 or SP2, respectively, and the
anchor primer). PCR products were directly cloned into
pGEM-T-Easy Vectors I (Promega, Mannheim, Germany)
and sequenced using the T7 and SP6 sites of the vector.
For primer sequences see table in additional file 1.
Results and Discussion
Definition of the PEX1 5’UTR
Both 5’ polymorphisms, c.-137 T > C and c.-53 C > G,
have been described as 5 ‘UTR polymorphisms implying
they become part of the mRNA. The PEX1 5’UTR was
reported to extend up to c.-245 according to PCR amplifi-
cation studies [19]. In PCRs with cDNA prepared from cul-
tivated primary human fibroblasts, however, we could not
amplify cDNA with primers upstream of or including c.-
137 (primers 455H, 455K, 455I, and OST542 in Figure 1).
Our analysis also included the primer used in a previous
study [19], here designated OST542 (Figure 1). In contrast,
all primers downstream of c.-137 (primers 455C, 455,
455G, 455E, 455F) could amplify the PEX1 cDNA. The
most upstream functional primer extended up to c.-123
suggesting that the polymorphism at c.-137 is not necessa-
rily part of the mRNA. Identification of the PEX1 tran-
scriptional start is of importance because a transcriptional
start at around c.-123 would render the upstream poly-
morphism at c.-137 a promotor polymorphism. For com-
parison, a database entry marked c.-96 as the PEX1 mRNA
start (NCBI Reference Sequence NM_000466.2). To
experimentally confirm the transcriptional start point of
PEX1, we conducted a 5’RACE (rapid amplification of
cDNA ends) experiment. The 5’ region of PEX1 mRNA
was reverse transcribed using a gene-specific internal pri-
mer, PCR amplified in two successive rounds and cloned
into a pGEM-T vector for sequencing. The longest 5’
extension of the cDNA that could be identified by this
approach extended to c.-120, giving no further indication
that the 5’ UTR of PEX1 stretches as far as c.-245. To gain
further insight into the PEX1 5’UTR/promotor region, we
searched the 500 bp upstream of the ATG for putative
transcription factor binding sites using the weight matrix-
based Match tool within the TRANSFAC database [20,21].
Results are summarized in the table in additional file 2.
This analysis shows that the region upstream c.-100 is cov-
ered by GC box elements that are bound by one of the
classical upstream transcription factors, Sp1 [22], also
arguing against a transcriptional start at c.-245.
In summary, PCR and RACE experiments, PEX1
cDNA database entries and a promoter analysis indicate
that the PEX1 polymorphism at c.-137 is not necessarily
a polymorphic site in the 5’ UTR but could also be a
polymorphism within the promoter. It is of interest that
242 bp upstream of the PEX1 start codon, the poorly
characterized ORF C7orf64 starts, extending on the
other DNA strand. Thus the PEX1 5’ region, previously
defined as UTR [19] coincides with the intergenic
regions between PEX1 and C7orf64 and would comprise
UTRs of both genes.
5’ Polymorphisms in a PEX1 patient population
PEX1 upstream polymorphisms bear the potential to
modulate the disease phenotype due to their influence on
PEX1 expression levels. We assessed the presence or
absence of the two known 5’ polymorphisms at c.-137
and c.-53 in a well-characterized PBD patient collection
with PEX1 mutations [12]. PEX1 mutations in this
patient collection are deletions (11 out of 60 alleles),
insertions (12/60), and point mutations (34/60). In three
patients, only one affected allele has been identified so far
(Table 1). The two most common mutations are the mis-
sense mutation c.2528 G > A in exon 15 (22 out of 60
alleles) resulting in an amino acid exchange of glycine to
aspartate (p.Gly843Asp or G843D), and the insertion
c.2097_2098insT in exon 13 (10/60 alleles) leading to a
frameshift after isoleucin in position 700 and a premature
termination codon (PTC). Altogether, 20 of the 60 alleles
include PTCs, leading to potentially more severe pheno-
types. Four constellations of the 5’ polymorphisms were
identified in the patient collective of 30 patients. We
found the common constellation (c.-137 TT and c.-53
CC) in 13 (43%) of the patients and, likewise 11 (37%)
heterozygous carriers (c.-137 TC and c.-53 GC). The 5’
polymorphism at c.-137 alone in combination with a
wild-type allele at c.-53 (c.-137 TC and c.-53 CC)
appeared in three (10%) of the PEX1 patients. Another
three (10%) were homozygous for both polymorphisms
(c.-137 CC and c.-53 GG). The three patients with a c.-
137T > C transition without the c.-53C > G transversion
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Figure 1 Analysis of the 5’ region of PEX1. Schematic representation of the PEX1 5’ region. Positions c.-137, c.-53 and the start codon are
marked. Primers that in combination with the reverse primer Pec10 or PEX1- Ex 2 (Exon 2) give PCR products are marked in light gray (cDNA
template). Primers that do not yield PCR products are marked in dark gray. In our analysis only primers downstream of c.-137 could be used to
amplify sequences from PEX1 cDNA. These results were confirmed by RACE.
Table 1 Distribution of 5’ polymorphisms in a cohort of PEX1 peroxisome biogenesis disorder patients
Patient 1st mutation Amino acids Exon hom/
het








ZS1 c.2226+2T > C r.2072_2416del p.
Ala691_Lys806
delinsGlu
intr13 hom 2 TT CC
ZS2 c.274G > C p.Val92Leu 3 hom 23 TT CC
ZS3 c.2083_2085del p.695del Met 13 hom 3 TT CC
ZS4 c.3691_3694del p.Gln1231HisfsX3 23 hom 3 TT CC
ZS5 c.2383C > T p.Arg795X 14 het c.2584-2A > G p.Val530ArgfsX34 Intron
15
het 4 TT CC
ZS6 c.3038G > A p.Arg1013His 20 het c.3287C > G p.Ser1096X 21 het 5 TT CC




het > 170 TT CC
ZS8 c.2528G > A p.Gly843Asp 15 het 2nd mutation? 70 TT CC
ZS9 c.2528G > A p.Gly843Asp 15 hom > 187 TT CC
ZS10 c.2528G > A p.Gly843Asp 15 hom > 214 TT CC
ZS11 c.2528G > A p.Gly843Asp 15 hom TT CC
ZS12 c.2528G > A p.Gly843Asp 15 hom > 240 TT CC
ZS13 c.2528G > A p.Gly843Asp 15 hom 2 TT CC
ZS14 c.724G > A p.Val242Ile 5 het 2nd mutation? 3 TC GC
ZS15 c.94_96del p.Pro32del 1 het c.2981T > C p.Leu994Pro 19 het TC GC
ZS16 c.911_912del p.Ser304fsX2 5 het c.2387T > C p.Leu796Pro 14 het 33 TC GC
ZS17 c.2528G > A p.Gly843Asp 15 hom 5 TC GC
ZS18 c.2528G > A p.Gly843Asp 15 hom TC GC
ZS19 c.2097_2098insT p.Ile700TyrfsX42 13 het c.1952_1960dup p.W653_M654ins
TVW
12 het 10 TC GC
ZS20 c.2097_2098insT p.Ile700TyrfsX42 13 het c.2528G > A p.Gly843Asp 15 het TC GC
ZS21 c.2097_2098insT p.Ile700TyrfsX42 13 het c.2528G > A p.Gly843Asp 15 het > 214 TC GC
ZS22 c.2097_2098insT p.Ile700TyrfsX42 13 het c.3037C > G p.Arg1013G 20 het 3 TC GC
ZS23 c.2097_2098insT p.Ile700TyrfsX42 13 het c.3124A > C F1042V het > 120 TC GC
ZS24 c.2097_2098insT p.Ile700TyrfsX42 13 het c.2916delA p.Gly973AlafsX16 18 het 3 TC GC
ZS25 c.2528G > A p.Gly843Asp 15 het c.1439delT p.Leu480TrpfsX2 7 het 18 TC CC
ZS26 c.2528G > A p.Gly843Asp 15 het 2nd mutation? TC CC
ZS27 c.2528G > A p.Gly843Asp 15 het c.2614C > T p.Arg872X 16 het TC CC
ZS28 c.2097_2098insT p.Ile700TyrfsX42 13 hom 11 CC GG
ZS29 c.2097_2098insT p.Ile700TyrfsX42 13 hom 5 CC GG
ZS30 c.2528G > A p.Gly843Asp 15 het c.249insT p.Leu84SerfsX24 2 het 3 CC GG
The table displays the 5’ polymorphisms and the previously identified exonic mutations in 30 PEX1 patients. Mutations c.2528 G > A and c.2097_2098insT are
especially common. Homozygosity (hom.) is inferred from the absence of heterozygosity in the sequencing reaction and the absence of a second site mutation
in PEX1. In three patients, ZS 8, ZS 14, and ZS 26, the second mutation is not identified. The 5’ polymorphism genotypes were determined by direct sequencing.
Four possible constellations of the 5’ polymorphisms were identified in the patient collective. Patients’ survival is indicated where this information was available.
> before number of months indicates patients that are alive and reached the respective age at the last follow-up in 2010.
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indicated that the c.-137T > C transition can be present
in the absence of the c.-53C > G transversion. This con-
stellation was not present in the patient cohort analysed
by Maxwell and colleagues [19]. On the background of
this polymorphism constellation PEX1 expression could
potentially be reduced to a stronger extent than caused
by the patients’ PEX1 mutations alone. The polymorphic
constellations identified in this study (TT CC, TC GG,
CC GG, and TC CC) are four of a total of nine possible
constellations. These four constelations can be explained
by existence of only three alleles: -137C -53G, -137T
-53C, and the rare -137C -53C. This would be the most
parsimonious, but still speculative interpretation.
In sum, the allele frequency of the c.-137T > C poly-
morphism in our patient cohort was 33% (20/60), com-
pared to 14.9% in the European population (NCBI single
nucleotide polymorphism (SNP) database). Interestingly,
the allele frequency of the c.-53C > G polymorphism
was 28% (17/60) in our cohort, whereas in the healthy
population it is reported to range between 4.4 and 7.8%
(NCBI SNP database).
We next analysed the distribution of PEX1 5’ poly-
morphisms in relation to the two most common PEX1
mutations. Table 2 shows the distribution of 5’ poly-
morphisms in relation to c.2097_2098insT. Of eleven
heterozygous patients (c.-137 TC and c.-53 GC), six
were heterozygous for the insertion c.2097_2098insT.
The remaining five patients did not carry the insertion.
The three patients with the heterozygous polymorphism
only at position c.-137 (c.-137 TC and c.-53 CC) did not
carry the c.2097_2098insT insertion and both homozy-
gous patients (c.-137 CC and c.-53 GG) were homozy-
gous for c.2097_2098insT. None of our patients with a
wild-type configuration at both polymorphism sites (c.-
137 TT und c.-53 CC) carries the c.2097_2098insT
insertions. We could thus confirm that the second most
common PEX1 allele, 2097_2098insT, is coupled to the
c.-137 T > C c.-53 C > G constellation and probably
evolved on the basis of this allele (Table 2). The evolu-
tion of the 2097_2098insT allele on the basis of the c.-
137 T > C c.-53 C > G constellation also explains the
overrepresentation of the c.-53C > G polymorphism in
our cohort.
Table 3 shows the distribution of these polymorphisms
in relation to the most common PEX1 mutation, p.
Gly843Asp. The 13 patients with the common sequence
at positions c.-137 and c.-53 and the 11 patients with the
two heterozygous 5’ polymorphisms distributed equally
in relation to the p.Gly843Asp mutation. One heterozy-
gous p.Gly843Asp patient was found to carry the rare
homozygous c.-137 CC c.-53 GG constellation. This indi-
cated that the p.Gly843Asp allele can be found in combi-
nation with any of the four possible 5’ alleles and that the
p.Gly843Asp mutation and the 5’ polymorphisms evolved
independently of each other.
Tables 2 and 3 also indicate the expected effect of the
polymorphisms on PEX1 gene expression levels follow-
ing the analysis of Maxwell et al. [19]. It was found that
c.-137 T > C polymorphism decreased the PEX1 gene
expression by 50% (↓), whereas the c.-53 C > G poly-
morphism increased PEX1 expression by approximately
25% (↑) when analyzed in a luciferase reporter study
[19]. A combination of both 5’ polymorphisms did not
lead to a significant change in PEX1 gene expression.
To evaluate a possible effect of PEX1 5’ polymorphisms
on the severity of the patient phenotype we included the
5’ polymorphisms in a genotype-phenotype analysis.
Genotype-Phenotype-Correlation
With respect to the common exonic PEX1 mutations, a
genotype-phenotype correlation has been described
[9,12,23,24]. Generally, PEX1 alleles that lead to a PTC
(P), caused by frameshift or nonsense mutations, lead to
more severe phenotypes than alleles with a missense
mutation (M). It is thus possible to classify patients in
three groups, depending on the combinations of PTC and
M: MM (type 1), PM (type 2), PP (type 3). In order to
limit the genotypic classes to three, we included the
patients with short insertions that do not result in PTC in
the type 1 group and the more extensive deletions
together with other deletions resulting in PTCs in the
PTC group. We undertook this analysis with our patient





c.-137T > C polymorphism c.-53C > G polymorphism c.2097_2098insT genotype
13 8 TT CC -
3 0 TC (↓) CC -
5 1 TC (↓) GC (↑) -
6 15 TC (↓) GC (↑) het
2 1 CC (↓↓) GG (↑↑) hom
Het and hom refer to the heterozygous and homozygous presence of the c.2097_2098insT genotype, respectively. Our study identified a new genetic
constellation, that is the potentially expression reducing 137T > C transition in the absence of the c.-53C > G transversion (marked in bold). The arrows refer to
the expected effect on PEX1 expression [19].
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cohort and plotted the time of survival as a measure of
phenotypic severity on the y-axis (Figure 2).
This representation confirms that the type 3 genotype
results in the most severe phenotype with an average sur-
vival of only 4.7 months (six patients). This group also
includes patient ZS01 with a homozygous deletion of 115
amino acids. The average survival in the patient group
with a combination of a missense mutation and a PTC
(type 2) is 50.8 months (eight patients). This group also
includes patient ZS19 with a three-base pair insertion in
combination with the common p.Ile700TyrfsX42 muta-
tion. Patients with missense mutations on both PEX1
copies (type 1) show the longest survival, 106 months on
average (eight patients). The patient group generally
associated with the longest survival can be divided into
two groups of survival of less than 40 months or 8.2
months on average (four patients) and more than 170
months, or 203 months on average (Figure 2). It has to
be noted that patients with a survival of more than 100
months were alive at the time of the submission of this
manuscript, so the longer survival rates can be prognosti-
cally used as a lower limit only.
We also indicated the 5’ polymorphisms within each of
these groups and found that all but one patient of known
survival in the type 1 group have the common 5’ genotype
c.-137 TT c.-53 CC. This means that the differentiation in
survival in the type 1 group is not due to differences in the
known 5’ polymorphisms, and, more generally, that differ-
ences in 5’ polymorphisms are not the cause for the differ-
ent survival of patients with the same mutations in PEX1.
On the other side, conclusions that can be drawn from
this analysis are limited by the absence of a pair of patients
with functionally different 5’ polymorphisms and with the
same exonic genotype. Extreme differences in survival of
patients with identical exonic mutations and 5’ poly-
morphisms suggest, however, that these differences cannot
be attributed to the 5’ polymorphisms.
Conclusions
Our study suggests that only the PEX1 5’ polymorphic
site at c.-53 is part of the 5’ UTR while the
Table 3 PEX1 5’ polymorphisms with respect to the most common mutation c.2528G > A (p.Gly843Asp)
No. of patients c.-137T > C polymorphism c.-53C > G polymorphism c.2528G > A (p.Gly843Asp) genotype
2 TT CC het
5 TT CC hom
6 TT CC -
2 TC (↓) GC (↑) het
2 TC (↓) GC (↑) hom
7 TC (↓) GC (↑) -
3 TC (↓) CC het
0 TC (↓) CC hom
0 TC (↓) CC -
1 CC(↓↓) GG (↑↑) het
0 CC(↓↓) GG (↑↑) hom
2 CC(↓↓) GG (↑↑) -
Het and hom refer to the heterozygous and homozygous presence of the c.2528G > A genotype, respectively. The c.2528G > A allele is found in combination






























M = Missense mutation
P = Premature termination
-137 TC   -53 CC
-137 TT   -53 CC
-137 TC   -53 GC
-137 CC  -53 GG
5' Polymorphism
PEX1 Genotype
Figure 2 Genotype-Phenotype-Correlation in PEX1 patients
with known survival. Patients were grouped according to their
genotypes into patients with missense mutations (M) on both
alleles (type 1, MM), with premature termination codons (PTCs, P)
on both alleles (type 3, PP), or with a combination of a PTC with a
missense mutation (type 2, MP). To limit the genotypic classes to
three, we grouped short insertions that do not result in PTC
together with M, and more extensive deletions together with the P
alleles. 5’ polymorphisms are marked in color. Numbers in circles
refer to ZS patient numbers as in Table 1. Patients with survival of
more than 100 months were alive at the time of submission of the
manuscript.
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polymorphism 137 bp upstream of the PEX1 start codon
might be part of the PEX1 promoter. The common
c.2528G > A (p.Gly843Asp) mutation appears to be
independent of a specific upstream polymorphism in
contrast to the second most common mutation,
c.2097_2098insT (p.Ile700TyrfsX42), that arose on the
basis of the -137 T > C c.-53 C > G polymorphic con-
stellation. A novel genotype-phenotype representation
with only three genetic categories allows distinguishing
groups of largely differing patient survival, but 5’ poly-
morphisms do not seem to further modulate patient
survival. We could not yet, however, identify patients
with identical PEX1 mutations and functionally different
5’ polymorphisms.
Additional material
Additional file 1: Primers used in this study. Table with list of
oligonucleotide primers used in this study.
Additional file 2: Transcription factor binding sites in the PEX1 5’
upstream region from c.-500 to c.-1. Table with results of an in silico
analysis of transcription factor binding sites in the PEX1 5’ region.
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